Ascendis Pharma (ASND) Reports Q2 EPS by EUR (1.46)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
August 10, 2022 4:01 PM EDTÂ Â U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022
  SKYTROFA revenue continued to double quarter-to-quarter, reaching 4.4 million in the second quarter
  With anticipated growth in U.S. revenues and approximately 1 billion of cash, cash equivalents, and marketable securities on hand, Ascendis is positioned to fulfill Vision 3x3 and become cash flow positive
  Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:... More
